ATE346849T1 - Ein verfahren zur herstellung von 4- 2-(aryl oder heterocyclo)-1h-imidazol-1-ylöbenzolsulfonamide - Google Patents

Ein verfahren zur herstellung von 4- 2-(aryl oder heterocyclo)-1h-imidazol-1-ylöbenzolsulfonamide

Info

Publication number
ATE346849T1
ATE346849T1 AT01123289T AT01123289T ATE346849T1 AT E346849 T1 ATE346849 T1 AT E346849T1 AT 01123289 T AT01123289 T AT 01123289T AT 01123289 T AT01123289 T AT 01123289T AT E346849 T1 ATE346849 T1 AT E346849T1
Authority
AT
Austria
Prior art keywords
alkyl
protected
halo
imidazole
aryl
Prior art date
Application number
AT01123289T
Other languages
English (en)
Inventor
Ish K Khanna
Richard M Weier
Paul W Collins
Yi Yu
Xiangdong Xu
Richard A Partis
Francis J Koszyk
Renee M Huff
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of ATE346849T1 publication Critical patent/ATE346849T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01123289T 1996-01-26 1997-01-24 Ein verfahren zur herstellung von 4- 2-(aryl oder heterocyclo)-1h-imidazol-1-ylöbenzolsulfonamide ATE346849T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59216796A 1996-01-26 1996-01-26

Publications (1)

Publication Number Publication Date
ATE346849T1 true ATE346849T1 (de) 2006-12-15

Family

ID=24369588

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01123289T ATE346849T1 (de) 1996-01-26 1997-01-24 Ein verfahren zur herstellung von 4- 2-(aryl oder heterocyclo)-1h-imidazol-1-ylöbenzolsulfonamide
AT97901952T ATE236130T1 (de) 1996-01-26 1997-01-24 Heterocyclisch substituierte imidazole zur behandlung von entzündungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97901952T ATE236130T1 (de) 1996-01-26 1997-01-24 Heterocyclisch substituierte imidazole zur behandlung von entzündungen

Country Status (12)

Country Link
EP (2) EP1193265B1 (de)
JP (1) JP2000503987A (de)
AT (2) ATE346849T1 (de)
AU (1) AU730642B2 (de)
DE (3) DE69737042D1 (de)
DK (2) DK1193265T3 (de)
ES (2) ES2274843T3 (de)
HK (1) HK1045843B (de)
NZ (1) NZ327022A (de)
PT (2) PT1193265E (de)
WO (1) WO1997027181A1 (de)
ZA (1) ZA97670B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
PL341984A1 (en) 1998-01-28 2001-05-07 Shionogi & Co Novel tricycle compounds
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6410562B1 (en) 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
ES2166710B1 (es) * 2000-04-25 2004-10-16 J. URIACH & CIA, S.A. Nuevos compuestos heterociclicos con actividad antiinflamatoria.
AU2001256705A1 (en) * 2000-05-15 2001-11-26 Grelan Pharmaceutical Co. Ltd. 1-(benzothiazol-2-yl)pyrazole derivatives and cox-2 inhibitors containing the same
US6555563B1 (en) * 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
AU2003216591A1 (en) * 2002-04-10 2003-10-20 Orichid Chemicals And Pharmaceuticals Limited Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
US6878735B2 (en) * 2002-05-31 2005-04-12 Board Of Trustees Of Michigan State University Multi-substituted imidazolines and method of use thereof
JP2005535642A (ja) 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
WO2004060367A1 (en) * 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
WO2005087747A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
CN102584695B (zh) * 2012-01-13 2014-02-19 江苏中邦制药有限公司 一种5-甲基烟酸的制备方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3264492B2 (ja) * 1992-01-13 2002-03-11 スミスクライン・ビーチャム・コーポレイション ピリジル置換イミダゾール
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
HK1045843B (en) 2007-03-02
NZ327022A (en) 1999-06-29
EP1193265A2 (de) 2002-04-03
DE69737042D1 (de) 2007-01-11
DE69720428T2 (de) 2004-02-12
AU1573997A (en) 1997-08-20
ES2197983T3 (es) 2004-01-16
ES2274843T3 (es) 2007-06-01
ATE236130T1 (de) 2003-04-15
AU730642B2 (en) 2001-03-08
DE69737042T8 (de) 2007-11-22
DK0880504T3 (da) 2003-07-21
EP0880504B1 (de) 2003-04-02
ZA97670B (en) 1998-04-16
DK1193265T3 (da) 2007-02-19
EP0880504A1 (de) 1998-12-02
EP1193265B1 (de) 2006-11-29
PT880504E (pt) 2003-08-29
EP1193265A3 (de) 2002-04-10
WO1997027181A1 (en) 1997-07-31
JP2000503987A (ja) 2000-04-04
DE69720428D1 (de) 2003-05-08
HK1045843A1 (en) 2002-12-13
DE69737042T2 (de) 2007-07-19
PT1193265E (de) 2007-03-30

Similar Documents

Publication Publication Date Title
DE69737042D1 (de) Ein Verfahren zur Herstellung von 4-i2-(Aryl oder Heterocyclo)-1H-imidazol-1-ylöbenzolsulfonamiden
ATE210648T1 (de) 3,4-substituierte pyrazole zur behandlung von entzündungen
KR880005093A (ko) 5-알킬벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 약제학적 조성물
ES2197160T3 (es) Antagonistas fibronogeno bicicliclos.
ATE185807T1 (de) Thiazolylbenzofuranderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten
AR030249A1 (es) Peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c, composicion farmaceutica que lo comprende, un metodo para su preparacion y el uso de los mismos para la manufactura de medicamentos y un metodo para modular el procesamiento de un polipeptido del virus
ATE315397T1 (de) Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen
ES2120728T3 (es) Inhibidores de la agregacion de plaquetas.
ES2183883T3 (es) Compuestos de imidazolilo sustituidos en 1,2 para el tratamiento de la inflamacion.
ES2160826T3 (es) Productos para la proteccion de cosechas.
DE122009000010I1 (de) Krampflösende, enantiomere aminosäure-derivate
DE69326804D1 (de) 1-Aminoacetamidopyrrole und 1-Amino-2-(substituierte)-Pyrrole und ihre Verwendung zur Behandlung von neurodegenerativen Störungen
ES2110115T3 (es) Inhibidores de la agregacion de plaquetas.
DK0804418T3 (da) Platelataggregationshæmmere
DE69417573D1 (de) Tricyclische derivate und phamazeutische zusammensetzungen die sie enthalten
WO2005060713A3 (en) Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
ATE203397T1 (de) Verfahren zur herstellung einer festen arzneimitteldosierungsform
DK0844241T3 (da) Inhibitor af narkotisk analgetisk afhængighed/resistensudvikling
EA200101170A1 (ru) Галоидпроизводные 9-деоксо-9а-аза-9а-гомоэритромицина а
KR900001696A (ko) 궤양치료 활성을 갖는 1.4-디아제핀 유도체
KR100348888B1 (en) Method for relieving violence and spare diet of estrous deer and method for promoting growth of antlers thereof
DE69622393D1 (de) Neue verwendung von pyrazolopyridinverbindungen
NZ314517A (en) 1-substituted phenyl-4,5-dihydro-3H-2,3-benzodiazepine derivatives and pharmaceutical compositions thereof
RU99104811A (ru) Мускариновые антагонисты

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1193265

Country of ref document: EP

REN Ceased due to non-payment of the annual fee